Methylene Blue Treatment Unveils Blood Biomarkers in Fatal Cerebral Malaria

Dr. Malleret’s describes a macaque model of cerebral malaria using Plasmodium coatneyi and explores the use of Methylene Blue as both a treatment and a tool to study disease severity. The team identified nine key blood biomarkers that distinguish severe cerebral malaria from mild cases and validated these findings across multiple datasets, highlighting the central role of neutrophils. Methylene Blue treatment not only reversed disease pathology in the brain but also offers a low-cost, low-toxicity therapeutic option, particularly relevant in regions with rising drug resistance. The study provides a robust platform for drug screening and understanding the mechanisms underlying severe malaria.